tiprankstipranks
Trending News
More News >
BeOne Medicines (ONC)
NASDAQ:ONC
US Market

BeOne Medicines (ONC) Drug Pipeline

Compare
838 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Aromatase Inhibitor, Bg-75202, Cdk4 Inhibitor, Estrogen Receptor Antagonist
Breast Cancer, Advanced Solid Tumor
Phase I
Not Yet Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Oct 28, 2025
Bg-C0902
Advanced Solid Tumor, Solid Tumors
Phase I
Not Yet Recruiting
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
Sep 12, 2025
Zanubrutinib
Waldenström's Macroglobulinemia
Phase IV
Not Yet Recruiting
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia
Sep 05, 2025
Sonrotoclax, Zanubrutinib, Bg-71332
Healthy Volunteers
Phase I
Not Yet Recruiting
A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults
Aug 19, 2025
Bgb-45035
Rheumatoid Arthritis
Phase II
Recruiting
A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis
Jul 28, 2025
Oxaliplatin, Capecitabine, Cisplatin, Leucovorin, 5-Fluorouracil (5-FU), Subcutaneous Tislelizumab, Intravenous Tislelizumab
Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma
Phase III
Recruiting
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Jun 20, 2025
Bgb-16673
Chronic Spontaneous Urticaria
Phase I
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria
May 22, 2025
Pirtobrutinib, Bgb-16673
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase III
Recruiting
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
May 07, 2025
Rituximab, Bendamustine, Methylprednisolone, Bgb-16673
Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
Phase III
Recruiting
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
May 06, 2025
Rituximab, Venetoclax, Obinutuzumab, Sonrotoclax
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase III
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Apr 17, 2025

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does BeOne Medicines (ONC) have in its pipeline
      ONC is currently developing the following drugs: Aromatase Inhibitor, Bg-75202, Cdk4 Inhibitor, Estrogen Receptor Antagonist, Bg-C0902, Zanubrutinib. These drug candidates are in various stages of clinical development as the company works toward FDA approval.